Ken Horne

Ken holds Bachelor's and Master's degrees in mechanical engineering from Stanford University. He has been involved in Stanford's BioDesign program and StartX.

​

He lives in San Francisco with his wife and two children.

Ken Horne is an experienced healthcare investor, entrepreneur and executive with over two decades of professional success. He currently serves as the Managing Partner of AN Ventures, a Japan focused biotech fund. Previously he was the chairperson of RDiscovery, Remiges Ventures’ company creation entity. In this role, he has helped start and invest in Capacity Bio, Typewriter Therapeutics, and Viage Therapeutics as President or CEO. Previously as an entrepreneur, he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics. Before that, he was a founding member of TauTona Group, an early-stage life science venture capital fund backed by Stanford Management Company and other top LPs. He started his career working for The Foundry, a preeminent medtech incubator, and he was an early or founding employee at eValve (acquired by Abbott), Cierra (acquired by Terumo) and others.

Ken is a member of Class 17 and served his fellowship at TauTona Group under the mentorship of Mark Foley.

​

Ken was awarded the Jeff Timmons Memorial Award, recognizing his outstanding service to his class and the Kauffman Fellows Program.